Nearly every reliable resource on age-related macular degeneration (AMD) will reveal that more women than men are affected by the disease. Some even go so far as to offer questionable statistics like “About 2/3 of people with AMD are women and 1/3 men”.(1) To explain, writers offer that women live longer than men, or that [Read More]
Author: Dan Roberts
Eylea Approved for Diabetic Retinopathy Treatment
Regeneron Pharmaceuticals, Inc. has announced FDA approval of Eylea (aflibercept) injection to treat all stages of diabetic retinopathy. Eylea is already approved for treatment of three conditions: neovascular (wet) age-related macular degeneration, macular edema resulting from retinal vein occlusion, and diabetic macular edema. This additional use of Eylea for diabetic retinopathy was approved based upon [Read More]
Need For Improvement in Hospital Care For Vision-Impaired Patients
Recent research spotlights a need to address certain risks and incapacities with which people with visual impairment are faced during hospital stays. Vision-impaired hospital patients have worse clinical outcomes, more readmissions, longer lengths of stay, and higher costs of care than non-vision-impaired patients, according to the authors. The article, published April 4, 2019 in JAMA [Read More]
A portable hand-held electronic reader for less than $200
Low vision presents many challenges in managing daily living activities, with one of the most important being spot reading. This includes reading labels, instructions, envelope addresses, checkbooks, receipts, menus, food containers, recipes, clocks, signs, written notes, currency values, and on and on. With loss of functional eyesight, such normally routine tasks require either accommodating, seeking [Read More]
Egg Consumption Linked to Lower Risk of wet AMD
Australian investigators have found that patients who consumed two or more eggs per week reduced their risk of developing wet age-related macular degeneration (wAMD) by 62% compared to those who consumed 1 or fewer. More than 3,600 patients from the Blue Mountains Eye Study, aged 49+ years, were examined across a 15-year follow-up period. 2,034 [Read More]